5-fluorouracil-associated cardiotoxicity
Roosia, S.Kumar.
Indian Heart Journal 54(3): 325; Author Reply 325
2002
ISSN/ISBN: 0019-4832 PMID: 12216937 Document Number: 545765
Document emailed within 1 workday
Related Documents
Shaib, W.; Lee, V.; Saif, M.W. 2009: Bolus 5-Fluorouracil as an alternative modality to infusion 5-Fluorouracil in a patient with rectal cancer and capecitabine-induced cardiotoxicity In Vivo 23(5): 821-8261994: Fluorouracil and cardiotoxicity Medical Journal of Australia 160(7): 445
Weng, M.C.; Wang, W.B.; Chao, T.Y. 1995: Cardiotoxicity related to 5-fluorouracil chemotherapy: a report of two cases Zhonghua Yi Xue Za Zhi 55(3): 266-269
Stathopoulos, G.P.; Malamos, N.A.; Dontas, I.; Deliconstantinos, G.; Perrea-Kotsareli, D.; Karayannacos, P.E. 1998: Inhibition of adriamycin cardiotoxicity by 5-fluorouracil: a potential free oxygen radical scavenger Anticancer Research 18(6a): 4387-4392
Shahrokni, A.; Rajebi, M.R.; Harold, L.; Saif, M.W. 2009: Cardiotoxicity of 5-fluorouracil and capecitabine in a pancreatic cancer patient with a novel mutation in the dihydropyrimidine dehydrogenase gene Jop: Journal of the Pancreas 10(2): 215-220
Schumacher, K. 2000: Comparison of fluorouracil + folinic acid, fluorouracil + levamisole and fluorouracil + folinic acid + levamisole in Dukes' B and C colon cancer: NSABP Trial C-04 Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft . 176(5): 239-240
Shirasaka, T.; Shimamoto, Y.; Kato, T.; Fukushima, M. 1998: Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil Gan to Kagaku Ryoho. Cancer and ChemoTherapy 25(3): 371-384
El Sayed, Y.M.; Sadée, W. 1983: Metabolic activation of R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil (ftorafur) to 5-fluorouracil by soluble enzymes Cancer Research 43(9): 4039-4044
Yamashita, K.; Mitani, K.; Morishita, Y.; Inoue, K. 1989: The concentration of 5-fluorouracil in blood and tissues of the patients with carcinoma of the cervix after administration of UFT and 5-fluorouracil Gan to Kagaku Ryoho. Cancer and ChemoTherapy 16(4 Part 1): 767-773
Fujii, S.; Kitano, S.; Ikenaka, K.; Fukushima, M.; Nakamura, H.; Maehara, Y.; Shirasaka, T. 1980: Effect of coadministration of thymine or thymidine on the antitumor activity of 1-(2-tetrahydrofuryl)-5-fluorouracil and 5-fluorouracil Gan 71(1): 100-106
Iigo, M.; Kuretani, K.; Hoshi, A. 1981: Metabolic fate on 1-hexylcarbamoyl-5-fluorouracil and 5-fluorouracil in mice bearing ascites sarcoma 180 Journal of the National Cancer Institute 66(2): 345-349
Tamemasa, O.; Tezuka, M. 1983: Antitumor effect of 5-fluorouracil in combination with some additives which stimulate the formation of antineoplastic 5-fluorouracil nucleotides Gan 74(2): 285-290
Yee, L.K.; Allegra, C.J.; Steinberg, S.M.; Grem, J.L. 1992: Decreased catabolism of fluorouracil in peripheral blood mononuclear cells during combination therapy with fluorouracil, leucovorin, and interferon alpha-2a Journal of the National Cancer Institute 84(23): 1820-1825
Toide, H.; Akiyoshi, H.; Minato, Y.; Okuda, H.; Fujii, S. 1977: Comparative studies on the metabolism of 2-(tetrahydrofuryl)-5-fluorouracil and 5-fluorouracil Gan 68(5): 553-560
Furuhata, T.; Kawakami, M.; Okita, K.; Kimura, Y.; Kihara, C.; Tsuruma, T.; Ohmura, T.; Yamaguchi, K.; Hata, F.; Katsuramaki, T.; Sasaki, K.; Hirata, K. 2006: Plasma level of a 5-fluorouracil metabolite, fluoro-beta-alanine correlates with dihydropyrimidine dehydrogenase activity of peripheral blood mononuclear cells in 5-fluorouracil treated patients Journal of Experimental and Clinical Cancer Research: Cr 25(1): 79-82
Van Cutsem, E.; Blijham, G.H. 1999: Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group Seminars in Oncology 26(1 Suppl. 5): 13-20
Kalofonos, H.P.; Papakostas, P.; Makatsoris, T.; Papamichael, D.; Vourli, G.; Xanthakis, I.; Aravantinos, G.; Papadimitriou, C.; Pentheroudakis, G.; Varthalitis, I.; Samelis, G.; Syrigos, K.N.; Xiros, N.; Stavropoulos, M.; Kosmidis, P.; Christodoulou, C.; Linardou, H.; Skondra, M.; Pectasides, D.; Economopoulos, T.; Fountzilas, G. 2010: Irinotecan/fluorouracil/leucovorin or the same regimen followed by oxaliplatin/fluorouracil/leucovorin in metastatic colorectal cancer Anticancer Research 30(10): 4325-4333
Ohtani, H.; Arimoto, Y.; Nishio, K.; Kanamiya, Y.; Oba, H.; Adachi, K.; Shintani, M.; Nakamura, R.; Yui, S. 2008: Efficacy and toxicity of fluorouracil, leucovorin plus oxaliplatin (FOLFOX4 and modified FOLFOX6) followed by fluorouracil, leucovorin plus irinotecan(FOLFIRI)for advanced or metastatic colorectal cancer--case studies Gan to Kagaku Ryoho. Cancer and ChemoTherapy 35(10): 1769-1774
Taguchi, T.; Sakai, K.; Terasawa, T.; Wada, H. 1986: Results of clinical trials with a CMitF (cyclophosphamide, mitoxantrone, and 5-fluorouracil) regimen versus a CAF (cyclophosphamide, adriamycin, and 5-fluorouracil) regimen in advanced/relapsed breast cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 13(9): 2820-2828
Recalcatri, F.; Villa, A.; Belli, C. 1982: Adriamycin cardiotoxicity Giornale Italiano di Cardiologia 12(8): 612-616